Elif Tutun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elif Tutun has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Perihan Unak
Ege University, Institute of Nuclear Sciences, Department of Nuclear Applications, Bornova Izmir, 35100, Turkey
4 shared publications - Volkan Yasakci
Ege University, Institute of Nuclear Sciences, Department of Nuclear Applications, Bornova Izmir, 35100, Turkey
3 shared publications - Agnieszka Majkowska-Pilip
Institute of Nuclear Chemistry and Technology, Warsaw, Poland
2 shared publications - Aleksander Bilewicz
Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Warsaw, Poland
2 shared publications - Kadriye Busra Karatay
Department of Nuclear Applications, Institute of Nuclear Sciences, Ege University, İzmir, Turkey
2 shared publications - Kamil Wawrowicz
Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195 Warsaw, Poland
2 shared publications
Latest Publications
- Open Access
- 5 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 850
Multimodal Radiobioconjugates of Magnetic Nanoparticles Labeled with 44Sc and 47Sc for Theranostic Application
This study was performed to synthesize multimodal radiopharmaceutical designed for the diagnosis and treatment of prostate cancer. To achieve this goal, superparamagnetic iron oxide (SPIO) nanoparticles were used as a platform for targeting molecule (PSMA-617) and for complexation of two scandium radionuclides, 44Sc for PET imaging and 47Sc for radionuclide therapy. TEM and XPS images showed that the Fe3O4 NPs have a uniform cubic shape and a size from 38 to 50 nm. The Fe3O4 core are surrounded by SiO2 and an organic layer. The saturation magnetization of the SPION core was 60 emu/g. However, coating the SPIONs with silica and polyglycerol reduces the magnetization significantly. The obtained bioconjugates were labeled with 44Sc and 47Sc, with a yield higher than 97%. The radiobioconjugate exhibited high affinity and cytotoxicity toward the human prostate cancer LNCaP (PSMA+) cell line, much higher than for PC-3 (PSMA-) cells. High cytotoxicity of the radiobioconjugate was confirmed by radiotoxicity studies on LNCaP 3D spheroids. In addition, the magnetic properties of the radiobioconjugate should allow for its use in guide drug delivery driven by magnetic field gradient.
- 5 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 850
Open AccessMultimodal Radiobioconjugates of Magnetic Nanoparticles Labeled with 44Sc and 47Sc for Theranostic Application
This study was performed to synthesize multimodal radiopharmaceutical designed for the diagnosis and treatment of prostate cancer. To achieve this goal, superparamagnetic iron oxide (SPIO) nanoparticles were used as a platform for targeting molecule (PSMA-617) and for complexation of two scandium radionuclides, 44Sc for PET imaging and 47Sc for radionuclide therapy. TEM and XPS images showed that the Fe3O4 NPs have a uniform cubic shape and a size from 38 to 50 nm. The Fe3O4 core are surrounded by SiO2 and an organic layer. The saturation magnetization of the SPION core was 60 emu/g. However, coating the SPIONs with silica and polyglycerol reduces the magnetization significantly. The obtained bioconjugates were labeled with 44Sc and 47Sc, with a yield higher than 97%. The radiobioconjugate exhibited high affinity and cytotoxicity toward the human prostate cancer LNCaP (PSMA+) cell line, much higher than for PC-3 (PSMA-) cells. High cytotoxicity of the radiobioconjugate was confirmed by radiotoxicity studies on LNCaP 3D spheroids. In addition, the magnetic properties of the radiobioconjugate should allow for its use in guide drug delivery driven by magnetic field gradient.
- 1 March 2023
- Published by Galenos Yayinevi in Nuclear Medicine Seminars
- Vol. 9 (1) , 7-15
Current Approach to Potential Alpha Particle Emiting Radionuclides for Alpha Radionuclide Therapy
- 1 March 2023
- Published by Galenos Yayinevi in Nuclear Medicine Seminars
- Vol. 9 (1) , 7-15
Current Approach to Potential Alpha Particle Emiting Radionuclides for Alpha Radionuclide Therapy
- Open Access
- 24 February 2023
- Published by MDPI AG in Preprints.org
Multimodal Radiobioconjugates of Magnetic Nanoparticles Labeled with 44Sc and 47Sc for Theranostic Application
This study was performed to synthesize multimodal radiopharmaceutical designed for the diagnosis and treatment of prostate cancer. To achieve this goal, Super Paramagnetic Iron Oxide (SPIO) nanoparticles were used as a platform for targeting molecule (PSMA-617) and for complexation of two scandium radionuclides, 44Sc for PET imaging and 47Sc for radionuclide therapy. TEM and XPS images showed that the Fe3O4 NPs have a uniform cubic shape and a diameter from 38 to 50 nm. The Fe3O4 core are surrounded by SiO2 and an organic layer. The saturation magnetization of the SPION core was 60 emu/g. However, coating the SPIONs with silica and polyglycerol reduces the magnetization significantly. The obtained bioconjugates were labeled with 44Sc and 47Sc, with a yield higher than 97%. The radiobioconjugate exhibited high affinity and cytotoxicity towards the human prostate cancer LNCaP (PSMA+) cell line, much higher than for PC-3 (PSMA-) cells. High cytotoxicity of the radiobioconjugate was confirmed by radiotoxicity studies on LNCaP 3D-spheroids. In addition, the magnetic properties of the radiobioconjugate should allow for its use in guide drug delivery driven by magnetic field gradient.
- 24 February 2023
- Published by MDPI AG in Preprints.org
Open AccessMultimodal Radiobioconjugates of Magnetic Nanoparticles Labeled with 44Sc and 47Sc for Theranostic Application
This study was performed to synthesize multimodal radiopharmaceutical designed for the diagnosis and treatment of prostate cancer. To achieve this goal, Super Paramagnetic Iron Oxide (SPIO) nanoparticles were used as a platform for targeting molecule (PSMA-617) and for complexation of two scandium radionuclides, 44Sc for PET imaging and 47Sc for radionuclide therapy. TEM and XPS images showed that the Fe3O4 NPs have a uniform cubic shape and a diameter from 38 to 50 nm. The Fe3O4 core are surrounded by SiO2 and an organic layer. The saturation magnetization of the SPION core was 60 emu/g. However, coating the SPIONs with silica and polyglycerol reduces the magnetization significantly. The obtained bioconjugates were labeled with 44Sc and 47Sc, with a yield higher than 97%. The radiobioconjugate exhibited high affinity and cytotoxicity towards the human prostate cancer LNCaP (PSMA+) cell line, much higher than for PC-3 (PSMA-) cells. High cytotoxicity of the radiobioconjugate was confirmed by radiotoxicity studies on LNCaP 3D-spheroids. In addition, the magnetic properties of the radiobioconjugate should allow for its use in guide drug delivery driven by magnetic field gradient.
- 2 September 2021
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 35 (12) , e6435
Synthesis and morphological studies of Tc‐99m‐labeled lupulone‐conjugated Fe3O4@TiO2 nanocomposite, and in vitro cytotoxicity activity on prostate cancer cell lines
The purpose of this study was to develop a multifunctional theranostic probe for imaging (magnetic resonance imaging [MRI] and single‐photon emission computed tomography [SPECT]) and therapy (photodynamic therapy). For this purpose, Tc‐99m‐labeled lupulone‐conjugated Fe3O4@TiO2 nanocomposites (99mTc‐DTPA‐Fe3O4@TiO2‐HLP and 99mTc‐DTPA‐Fe3O4@TiO2‐ALP nanocomposites) were synthesized. The average diameter of the nanocomposites was 171 ± 20 nm as seen on transmission electron microscopy images. Fe3O4@TiO2 nanocomposites exhibited fluorescence spectra at an emission wavelength of 314 nm. Lupulone‐conjugated Fe3O4@TiO2 nanocomposites were spherical‐shaped with a suitable dispersion and without visible aggregation, and their radiolabeling yields were over 85%. Healthy (RWPE‐1 normal human prostate epithelial cell line) and cancer prostate cell lines (PC‐3 human prostate cancer cell line) were used to determine the in vitro biological behavior of the nanocomposites. The PC‐3 cells treated with lupulone‐conjugated Fe3O4@TiO2 nanocomposites showed a lower cell viability compared with RWPE‐1 cells treated with lupulone‐conjugated Fe3O4@TiO2 nanocomposites. Lupulone‐modified Fe3O4@TiO2 nanocomposites may serve in the future as a multifunctional probe for positron emission tomography (PET)/MRI, photodynamic therapy, and hyperthermia therapy of cancer.
- 2 September 2021
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 35 (12) , e6435
Synthesis and morphological studies of Tc‐99m‐labeled lupulone‐conjugated Fe3O4@TiO2 nanocomposite, and in vitro cytotoxicity activity on prostate cancer cell lines
The purpose of this study was to develop a multifunctional theranostic probe for imaging (magnetic resonance imaging [MRI] and single‐photon emission computed tomography [SPECT]) and therapy (photodynamic therapy). For this purpose, Tc‐99m‐labeled lupulone‐conjugated Fe3O4@TiO2 nanocomposites (99mTc‐DTPA‐Fe3O4@TiO2‐HLP and 99mTc‐DTPA‐Fe3O4@TiO2‐ALP nanocomposites) were synthesized. The average diameter of the nanocomposites was 171 ± 20 nm as seen on transmission electron microscopy images. Fe3O4@TiO2 nanocomposites exhibited fluorescence spectra at an emission wavelength of 314 nm. Lupulone‐conjugated Fe3O4@TiO2 nanocomposites were spherical‐shaped with a suitable dispersion and without visible aggregation, and their radiolabeling yields were over 85%. Healthy (RWPE‐1 normal human prostate epithelial cell line) and cancer prostate cell lines (PC‐3 human prostate cancer cell line) were used to determine the in vitro biological behavior of the nanocomposites. The PC‐3 cells treated with lupulone‐conjugated Fe3O4@TiO2 nanocomposites showed a lower cell viability compared with RWPE‐1 cells treated with lupulone‐conjugated Fe3O4@TiO2 nanocomposites. Lupulone‐modified Fe3O4@TiO2 nanocomposites may serve in the future as a multifunctional probe for positron emission tomography (PET)/MRI, photodynamic therapy, and hyperthermia therapy of cancer.